Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

Technical Trend Overview and Price Movement

On 22 Sep 2026, Dr Reddys Laboratories closed at ₹1,202.00, up from the previous close of ₹1,171.10, marking a daily gain of 2.64%. The intraday range was between ₹1,186.20 and ₹1,211.65, reflecting moderate volatility. The stock remains below its 52-week high of ₹1,414.40 but comfortably above the 52-week low of ₹1,080.05. This price action coincides with a technical trend shift from bearish to mildly bearish, signalling a tentative improvement in momentum but still cautionary for investors.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart, indicating that the short-term momentum is still lagging. However, the monthly MACD has improved to mildly bearish, suggesting that longer-term momentum is stabilising. This divergence between weekly and monthly MACD readings points to a potential bottoming process, but confirmation is required through sustained price action above key moving averages.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in a neutral zone. This absence of extreme overbought or oversold conditions implies that the stock is neither stretched on the upside nor deeply undervalued technically. Investors should monitor RSI for any decisive moves beyond the 70 or 30 thresholds, which could indicate stronger directional momentum.

Moving Averages and Bollinger Bands

Daily moving averages present a mildly bearish stance, with the stock price hovering near or slightly below key averages such as the 50-day and 200-day moving averages. This suggests that while the stock is attempting to regain upward momentum, it has yet to decisively break out of its recent consolidation phase. Bollinger Bands on weekly and monthly charts also indicate a mildly bearish environment, with the price trading near the lower band, signalling potential support but also caution for further downside risk.

Volume and On-Balance Volume (OBV) Analysis

Volume-based indicators provide further nuance to the stock’s technical profile. The On-Balance Volume (OBV) shows no clear trend on the weekly chart but remains bearish on the monthly timeframe. This divergence suggests that while short-term trading volumes are not decisively supporting a trend, longer-term selling pressure may still be present. Investors should watch for any sustained increase in OBV to confirm accumulation phases.

KST and Dow Theory Signals

The Know Sure Thing (KST) indicator remains bearish on the weekly chart but has improved to mildly bearish on the monthly chart, mirroring the MACD’s mixed signals. Meanwhile, Dow Theory assessments are mildly bullish on both weekly and monthly timeframes, indicating that the broader trend may be shifting towards recovery. This contrast between momentum oscillators and trend theory highlights the stock’s current technical uncertainty but also potential for upside if confirmed by price action.

Comparative Returns and Market Context

Dr Reddys Laboratories’ recent returns have outperformed the Sensex in the short term. Over the past week, the stock gained 3.53% compared to the Sensex’s modest 0.10% rise. Over one month, the stock returned 2.30% while the Sensex declined 3.46%. Year-to-date, the stock is down 5.43%, outperforming the Sensex’s 12.16% decline. Over one year, the stock’s loss of 9.13% is marginally better than the Sensex’s 9.40% fall. However, over longer horizons such as three and five years, Dr Reddys has underperformed the benchmark, with 5.97% and 23.79% returns respectively versus Sensex’s 13.03% and 26.87%. The ten-year return of 90.64% also trails the Sensex’s 162.59%, reflecting sector-specific challenges and competitive pressures.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Dr Reddys Laboratories a Mojo Score of 36.0, categorising it as a Sell with a recent downgrade from Hold on 13 Jul 2026. The mid-cap pharmaceutical company’s technical grade reflects the cautious stance warranted by its mixed momentum indicators and relative underperformance over medium to long-term periods. Investors should weigh these technical signals alongside fundamental factors before making allocation decisions.

Investment Implications and Outlook

Dr Reddys Laboratories’ technical indicators suggest a stock in transition. The shift from bearish to mildly bearish momentum, combined with mixed signals from MACD, KST, and Dow Theory, indicates that the stock may be attempting to stabilise after a period of weakness. However, the lack of strong RSI signals and bearish volume trends caution against premature optimism.

For investors, the current technical landscape implies a need for vigilance. A sustained break above key moving averages and confirmation from volume indicators would be necessary to upgrade the stock’s technical outlook. Conversely, failure to hold support near the lower Bollinger Band and continued bearish OBV trends could signal further downside risk.

Given the mid-cap status and sector-specific headwinds, Dr Reddys Laboratories remains a stock to watch closely. Its recent outperformance relative to the Sensex in the short term is encouraging, but longer-term underperformance and a Mojo Grade downgrade underscore the importance of a cautious approach.

Summary

In summary, Dr Reddys Laboratories Ltd’s technical momentum has improved slightly but remains fragile. Mixed signals from key indicators such as MACD, RSI, moving averages, and volume metrics reflect a stock at a crossroads. Investors should monitor upcoming price action and volume trends closely to gauge whether the stock can transition to a more bullish phase or revert to bearish territory.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today